In the real world, as opposed to the controlled environment of clinical trials, use of the Oncotype DX (Genomic Health) test may not be as cost-effective as was thought. The gene expression profile ...

BAAR, Switzerland, March 12, 2025--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the ...

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, ...

Genomic Health, Inc. has announced that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...